Tempest Therapeutics Stock Market Value
| TPST Stock | USD 2.35 0.01 0.42% |
| Symbol | Tempest |
Is there potential for Biotechnology market expansion? Will Tempest introduce new products? Factors like these will boost the valuation of Tempest Therapeutics. If investors know Tempest will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Tempest Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Tempest Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Tempest Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Tempest Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Tempest Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tempest Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Tempest Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Tempest Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tempest Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tempest Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Tempest Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Tempest Therapeutics or generate 0.0% return on investment in Tempest Therapeutics over 90 days. Tempest Therapeutics is related to or competes with OnKure Therapeutics, Kezar Life, Aligos Therapeutics, Xilio Development, PDS Biotechnology, Actinium Pharmaceuticals, and Barinthus Biotherapeutics. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat... More
Tempest Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tempest Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tempest Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 52.01 | |||
| Value At Risk | (9.56) | |||
| Potential Upside | 7.62 |
Tempest Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tempest Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tempest Therapeutics' standard deviation. In reality, there are many statistical measures that can use Tempest Therapeutics historical prices to predict the future Tempest Therapeutics' volatility.| Risk Adjusted Performance | (0.15) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (2.32) | |||
| Treynor Ratio | (2.21) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Tempest Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Tempest Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (2.20) | |||
| Mean Deviation | 4.76 | |||
| Coefficient Of Variation | (512.03) | |||
| Standard Deviation | 8.58 | |||
| Variance | 73.6 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.73) | |||
| Total Risk Alpha | (2.32) | |||
| Treynor Ratio | (2.21) | |||
| Maximum Drawdown | 52.01 | |||
| Value At Risk | (9.56) | |||
| Potential Upside | 7.62 | |||
| Skewness | (2.62) | |||
| Kurtosis | 14.35 |
Tempest Therapeutics Backtested Returns
Tempest Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.2, which indicates the firm had a -0.2 % return per unit of risk over the last 3 months. Tempest Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Tempest Therapeutics' Risk Adjusted Performance of (0.15), coefficient of variation of (512.03), and Variance of 73.6 to confirm the risk estimate we provide. The entity has a beta of 0.76, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tempest Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tempest Therapeutics is expected to be smaller as well. At this point, Tempest Therapeutics has a negative expected return of -1.71%. Please make sure to validate Tempest Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Tempest Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.35 |
Below average predictability
Tempest Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Tempest Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tempest Therapeutics price movement. The serial correlation of 0.35 indicates that nearly 35.0% of current Tempest Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.35 | |
| Spearman Rank Test | 0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.